Fundraising Fox
Nacuity Pharmaceuticals
Fort Worth, US · Founded 2016 · Delaware corporation · 1 known investors
Find your way into Nacuity Pharmaceuticals
Sign up to see every warm intro you have to Nacuity Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Nacuity Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Based on the page listing "Ophthalmic Pharmaceutical Consultant" and "Chief Clinical Officer" roles, Nacuity appears to be a pharmaceutical company focused on ophthalmology (eye care), though the page provides insufficient detail to confirm products, customer base, or market focus.
Founders & leadership
MW
Michael WallSVP & CSOHe has extensive experience in pharmaceutical development across multiple dosage forms and routes of administration, including solid oral, injectable, topical, and inhalation products, with particular expertise in ophthalmic formulations and regulatory affairs across North American, European, and Asia-Pacific markets.
DW
David WohlbergExecutive
JK
CL
Charles LieserExecutive
Board
EC
Emmett Cunningham, Jr.Board director
RS
Robin SteeleBoard director
RK
Rusty KelleyBoard director
GC
Gerald CagleBoard director
BY
Benjamin YerxaBoard director
Investors · 1
Funding
SEC filings, press & company announcements$31.2M disclosed across 4 of 5 rounds · 2016–2025
- Undisclosed amountSeries BJun 2022Source ↗
▶$8.4MraisedDec 2025 · 98 investors · PharmaceuticalsRule 506(b)
▶$8.4MraisedDec 2025 · 98 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Michael WallExecutive Officer
- Robin SteeleDirector
- David WohlbergExecutive Officer, Director
- Rusty KelleyDirector
- Gerald CagleDirector
- Jami KernExecutive Officer
- Benjamin YerxaDirector
- Emmett Cunningham, Jr.Director
- Halden ConnerExecutive Officer, Director
- Charles LieserExecutive Officer
- Offering amount
- $30M
- Amount sold
- $8.4M
- Minimum investment
- $9.4K
- Sales commissions
- $839.3K
- Placement agents
- Maxim Group LLC
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.6MraisedJan 2022 · 144 investors · BiotechnologyRule 506(b)
▶$11.6MraisedJan 2022 · 144 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David WohlbergExecutive Officer, Director
- Charles LieserExecutive Officer
- Halden ConnerExecutive Officer, Director
- Robert RuffoloDirector
- Robin SteelDirector
- Benjamin YerxaDirector
- Gerald CagleDirector
- Offering amount
- $17.4M
- Amount sold
- $11.6M
- Minimum investment
- $10K
- Sales commissions
- $1.4M
- Placement agents
- Clifford Adam Teller
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$9.2MraisedJul 2017 · 125 investors · BiotechnologyRule 506(b)
▶$9.2MraisedJul 2017 · 125 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Isaac BlechDirector
- Charles LieserExecutive Officer
- G. Michael Wall, Ph.D.Executive Officer
- Dr. Gerald D. CagleDirector
- David J. WohlbergDirector
- William Halden ConnerExecutive Officer, Director
- Richard Chin, M.D.Director
- Sanford HillsbergDirector
- Offering amount
- $10M
- Amount sold
- $9.2M
- Minimum investment
- $25K
- Sales commissions
- $922.7K
- Placement agents
- Clifford Adam Teller
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$2MraisedDec 2016 · 46 investors · PharmaceuticalsRule 506(b)
▶$2MraisedDec 2016 · 46 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- William Halden ConnerExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2M
- Minimum investment
- $10K
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Nacuity Pharmaceuticals went on to found or lead other companies.
Related companies · 2
NovartisNovartis is a pharmaceutical company that develops and markets prescription medicines for patients across therapeutic areas including multiple sclerosis, breast cancer, and inflammatory conditions. Its medicines include treatments for HR+/HER2- early breast cancer and polymyalgia rheumatica.
OphthalmologytimesOphthalmology Times is a medical news publication covering clinical research, drug approvals, and treatment developments in eye care for ophthalmologists and other eye care professionals. It publishes articles, videos, podcasts, a digital edition, and continuing medical education content.
Companies working in the same space as Nacuity Pharmaceuticals.
In the news
Frequently asked questions
- What does Nacuity Pharmaceuticals do?
- Based on the page listing "Ophthalmic Pharmaceutical Consultant" and "Chief Clinical Officer" roles, Nacuity appears to be a pharmaceutical company focused on ophthalmology (eye care), though the page provides insufficient detail to confirm products, customer base, or market focus.
- Who are Nacuity Pharmaceuticals's investors?
- Nacuity Pharmaceuticals's investors include Tarnagulla Ventures.
- How much funding has Nacuity Pharmaceuticals raised?
- Nacuity Pharmaceuticals has disclosed $31.2M raised across 4 of its 5 known rounds.
- Where is Nacuity Pharmaceuticals headquartered?
- Nacuity Pharmaceuticals is headquartered in Fort Worth, US.